Sela. | Cloud Better.


Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Our non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. Our global team operates from San Diego, United States as well as from Rehovot Israel.

The challenge

Nucleix turned to the Sela Group to assist with transition to the cloud environment from their current on prem solution. Nucleix also needed help designing and implementing cloud infrastructure for their new services and products. We designed and implemented the new environments, in which Nucleix will use for their SaaS solution. The system would require an environment that is highly scalable, as time grows, moreover, it should be extremely flexible and secure.

The solution

Our main goals were to create a well architected AWS cloud environment to migrate their existing 'On-Prem' solution and create Infrastructure for their new SaaS solution. Due to HIPPA regulation the environment must be secured and reliable so no clinical information will be exposed nor lost. Due to the sensitivity of the data DR mechanism was implemented. The network architecture was designed to allow minimal external access to the production account, and only via VPN access to the dev account. The entire environment was created using CDK and automated pipelines to ensure quick recovery in case of a failure.

The results

The entire environment infrastructure was designed to meet HIPPA regulations and then created using CDK following Well-Architected best practices. Also, automated pipelines were created to ensure quick recovery in case of a failure.